Nirsevimab has been shown to help prevent RSV-associated lower respiratory tract infection in healthy preterm infants, but its safety and efficacy in late preterm and term infants are unknown. New research findings are summarized in a short video.

To see the full article, follow this link: [ Ссылка ]

свернуть